BACKGROUND: Renal artery stenosis (RAS) causes renal injury partly via microvascular (MV) endothelial dysfunction and damage. Vascular endothelial growth factor (VEGF) is crucial for preservation of microvasculature and promotes vascular proliferation and endothelial repair. We have previously shown that MV rarefaction is associated with decreased VEGF in the kidney exposed to chronic RAS, accompanied by deteriorated renal function and fibrosis. We hypothesized that preserving the renal microcirculation in the stenotic kidney will halt the progression of renal damage. METHODS: Unilateral RAS was induced in 16 pigs. In eight, VEGF (0.05 micrograms/kg) was infused intra-renally at the onset of RAS. After 6 weeks, single-kidney haemodynamics and function were assessed using in vivo multi-detector computed tomography (CT). Renal microvessels, angiogenic pathways and morphology were investigated ex vivo using micro-CT, real-time PCR and histology. RESULTS: Blood pressure and degree of RAS was similar in RAS and RAS + VEGF pigs. Single-kidney renal blood flow (RBF) and glomerular filtration rate (GFR) were reduced in RAS compared to Normal (221.1 +/- 46.5 and 29.9 +/- 3.8 vs. 522.5 +/- 60.9 and 49.3 +/- 3.4 mL/min, respectively, P < 0.05), accompanied by decreased cortical MV density and increased renal fibrosis. Pre-emptive administration of VEGF preserved MV architecture, attenuated fibrosis and normalized RBF and GFR (510.8 +/- 50.9 and 39.9.1 +/- 4.1 mL/min, P = not significant vs. Normal). CONCLUSIONS: This study underscores the importance of the renal microcirculation in renovascular disease. Intra-renal administration of VEGF preserved renal MV architecture and function of the stenotic kidney, which in turn preserved renal haemodynamics and function and decreased renal fibrosis. These observations suggest that preventing renal MV loss may be a potential target for therapeutic approaches for patients with chronic renovascular disease.
BACKGROUND:Renal artery stenosis (RAS) causes renal injury partly via microvascular (MV) endothelial dysfunction and damage. Vascular endothelial growth factor (VEGF) is crucial for preservation of microvasculature and promotes vascular proliferation and endothelial repair. We have previously shown that MV rarefaction is associated with decreased VEGF in the kidney exposed to chronic RAS, accompanied by deteriorated renal function and fibrosis. We hypothesized that preserving the renal microcirculation in the stenotic kidney will halt the progression of renal damage. METHODS: Unilateral RAS was induced in 16 pigs. In eight, VEGF (0.05 micrograms/kg) was infused intra-renally at the onset of RAS. After 6 weeks, single-kidney haemodynamics and function were assessed using in vivo multi-detector computed tomography (CT). Renal microvessels, angiogenic pathways and morphology were investigated ex vivo using micro-CT, real-time PCR and histology. RESULTS: Blood pressure and degree of RAS was similar in RAS and RAS + VEGFpigs. Single-kidney renal blood flow (RBF) and glomerular filtration rate (GFR) were reduced in RAS compared to Normal (221.1 +/- 46.5 and 29.9 +/- 3.8 vs. 522.5 +/- 60.9 and 49.3 +/- 3.4 mL/min, respectively, P < 0.05), accompanied by decreased cortical MV density and increased renal fibrosis. Pre-emptive administration of VEGF preserved MV architecture, attenuated fibrosis and normalized RBF and GFR (510.8 +/- 50.9 and 39.9.1 +/- 4.1 mL/min, P = not significant vs. Normal). CONCLUSIONS: This study underscores the importance of the renal microcirculation in renovascular disease. Intra-renal administration of VEGF preserved renal MV architecture and function of the stenotic kidney, which in turn preserved renal haemodynamics and function and decreased renal fibrosis. These observations suggest that preventing renal MV loss may be a potential target for therapeutic approaches for patients with chronic renovascular disease.
Authors: T D Henry; K Rocha-Singh; J M Isner; D J Kereiakes; F J Giordano; M Simons; D W Losordo; R C Hendel; R O Bonow; S M Eppler; T F Zioncheck; E B Holmgren; E R McCluskey Journal: Am Heart J Date: 2001-11 Impact factor: 4.749
Authors: Alejandro R Chade; Oren P Mushin; Xiangyang Zhu; Martin Rodriguez-Porcel; Joseph P Grande; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: Hypertension Date: 2005-09-19 Impact factor: 10.190
Authors: M D Hariawala; J R Horowitz; D Esakof; D D Sheriff; D H Walter; B Keyt; J M Isner; J F Symes Journal: J Surg Res Date: 1996-06 Impact factor: 2.192
Authors: Xiang-Yang Zhu; Alejandro R Chade; Martin Rodriguez-Porcel; Michael D Bentley; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: Arterioscler Thromb Vasc Biol Date: 2004-08-12 Impact factor: 8.311
Authors: Alejandro R Chade; Michael D Bentley; Xiangyang Zhu; Martin Rodriguez-Porcel; Sara Niemeyer; Beatriz Amores-Arriaga; Claudio Napoli; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: J Am Soc Nephrol Date: 2004-07 Impact factor: 10.121
Authors: Alejandro R Chade; Martin Rodriguez-Porcel; Joerg Herrmann; Xiangyang Zhu; Joseph P Grande; Claudio Napoli; Amir Lerman; Lilach O Lerman Journal: J Am Soc Nephrol Date: 2004-04 Impact factor: 10.121
Authors: Elizabeth R Flynn; Jonathan Lee; Zachary M Hutchens; Alejandro R Chade; Christine Maric-Bilkan Journal: J Diabetes Complications Date: 2013-08-29 Impact factor: 2.852
Authors: Alfonso Eirin; Xiang-Yang Zhu; Zilun Li; Behzad Ebrahimi; Xin Zhang; Hui Tang; Michael J Korsmo; Alejandro R Chade; Joseph P Grande; Christopher J Ward; Robert D Simari; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Arterioscler Thromb Vasc Biol Date: 2013-02-21 Impact factor: 8.311